Built for the Gap Between
Proof and Scale

Pharmaceutical and biotechnology companies increasingly depend on specialized service providers and enabling technologies across the value chain. As outsourcing deepens, a growing share of industry spend flows to focused, high-value service partners. Yet many of these businesses fall into a structural funding gap — too mature for venture capital, yet not large enough or scaled for traditional private equity.

NewVale was founded to serve this gap. We partner with companies in the window between commercial proof points and commercial scale, providing right-sized capital and focused support to help evolve businesses into durable industry leaders.